Table 2 The effects of CYP3A4, CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus and sirolimus daily requirements, concentration/dose ratio after renal transplantation

CYP3A5 (6986A>G)

112

43

*1/*1+*1/*3

52

2.7 (1.7–2.9)

6.2 (5.6–7.4)

124 (113–165.4)

20

1.28 (1.00–1.56)

4.2 (5.75–7.2)

249 (248.7–409.6)

*3/*3

60

2.3 (1.6–2.9)*

6.8 (4.5–8.7)

184.4 (148–261.7)*

23

1.00 (1.00–1.00)*

4.0 (5.7–7.7)

389.1 (293.7–537.9)*

ABCB1 3435C>T

 CC

30

1.0 (1.0–3.2)

4.3 (1.9–6.8)

242.1 (110.2–374)

18

1.00 (1.00–1.00)

7.1 (5.1–7.6)

364.5 (310.6–574.3)

 CT

62

1.25 (1.3–2.1)

6.2 (4.1–7.5)

165.2 (115.9–205)

20

1.10 (1.00–1.20)

6.2 (3.3–7.8)

365.6 (177.6–498.6)

 TT

20

1.5 (1.0–2.0)

7.1 (5.5–10.2)

324 (214.1–559)

5

1.00 (0.65–1.5)

4.3 (3.75–6.75)

316.5 (217.9–549.8)

ABCB1 1236C>T

 CC

17

1.0 (1.0–2.0)

6.0 (3.7–9.5)

247 (104.6–441)

8

1.00 (1.00–1.75)

5.7 (3.0–7.1)

298.6 (128.6–364.6)

 CT

50

1.5 (1.0–2.0)

7.1 (5.7–8.5)

181.1 (142.8–268)

20

1.00 (1.00–1.50)

7.5 (4.8–7.9)

385.9 (264.8–628.9)

 TT

45

1.3 (1.1–2.0)

5.0 (3.9–5.4)

214 (167–245)

15

1.00 (0.9–1.00)

5.2 (4.1–7.5)

381.9 (278.6–48.9)

ABCB1 2677C>T/A

 CC

22

1.0 (1.0–2.0)

6.0 (3.7–9.5)

217 (104.6–441)

7

1.00 (1.00–1.75)

5.7 (3.0–7.1)

298.6 (128.6–364.6)

 CT

49

1.15 (1.0–2.0)

7.1 (5.7–8.5)

161.1 (142.8–268)

16

1.00 (1.00–1.50)

6.5 (4.8–7.9)

386.9 (264.8–628.9)

 TT

16

1.25 (1.1–2.0)

5.0 (3.9–5.4)

204 (167–245)

11

1.00 (0.9–1.00)

4.2 (4.1–7.5)

371.9 (278.6–48.9)

A

25

1.3 (1.1–2.0)

5.0 (3.9–5.4)

214 (167–245)

9

1.00 (0.9–1.00)

5.2 (4.1–7.5)

341.9 (278.6–48.9)

CYP3A4 (CYP3A4*22)

 CC

112

2.0 (1.0–2.0)

6.5 (5.2–8.7)

205.2 (126.9–324)

43

1.07 (0.86–1.65)

6.1 (5.3–7.8)

364.8 (248.7–525.8)

CYP3A4 (CYP3A4*18)

 TT

110

2.0 (1.0–2.0)

6.5 (5.2–8.7)

205.2 (126.9–324)

43

1.07 (0.86–1.65)

6.1 (5.3–7.8)

364.8 (248.7–525.8)

 CT+TT

2

2.0/3.0

7.0/6.4

214/323

0

/

/

/